About

About MannKind Corporation At MannKind, we are committed to developing and commercializing innovative therapeutic products and devices for people living with endocrine and orphan lung diseases. Our approach begins with our cutting-edge technology and is driven by solutions-based scientists and medical professionals who are dedicated to helping people experience the very best life has to offer. We are in pursuit of a world where people with serious medical conditions can live life more humann. MannKind focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with orphan lung and endocrine diseases. We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as IPF, PAH and NTM. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. MannKind Corporation is a biopharmaceutical company dedicated to transforming chronic use disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.